{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:11:18Z","timestamp":1792271478013,"version":"4.4.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["09.822"],"award-info":[{"award-number":["09.822"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["09.815"],"award-info":[{"award-number":["09.815"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU 09.807"],"award-info":[{"award-number":["TTU 09.807"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["09.914"],"award-info":[{"award-number":["09.914"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["09.816"],"award-info":[{"award-number":["09.816"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU 09.701"],"award-info":[{"award-number":["TTU 09.701"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-027123"],"award-info":[{"award-number":["INV-027123"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1201530"],"award-info":[{"award-number":["OPP1201530"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["101103053"],"award-info":[{"award-number":["101103053"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC2151-390873048"],"award-info":[{"award-number":["EXC2151-390873048"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.pt.2024.07.005","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T16:09:08Z","timestamp":1723133348000},"page":"829-845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["The long and winding road towards new treatments against lymphatic filariasis and onchocerciasis"],"prefix":"10.1016","volume":"40","author":[{"given":"Frederic","family":"Risch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kazakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5351-5812","authenticated-orcid":false,"given":"Sabine","family":"Specht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3096-2465","authenticated-orcid":false,"given":"Kenneth","family":"Pfarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4558-3417","authenticated-orcid":false,"given":"Peter U.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8671-3831","authenticated-orcid":false,"given":"Achim","family":"Hoerauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8885-418X","authenticated-orcid":false,"given":"Marc P.","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2024.07.005_bb0005","series-title":"Ending the Neglect to Attain the Sustainable Development Goals: a Road Map for Neglected Tropical Diseases 2021\u20132030","author":"WHO","year":"2020"},{"key":"10.1016\/j.pt.2024.07.005_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.01.010","article-title":"Control, elimination, and eradication efforts for neglected tropical diseases in the World Health Organization African region over the last 30 years - a scoping review","volume":"141","author":"Wolfe","year":"2024","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cnur.2019.02.007","article-title":"Lymphatic filariasis","volume":"54","author":"Lourens","year":"2019","journal-title":"Nurs. Clin. North Am."},{"key":"10.1016\/j.pt.2024.07.005_bb0020","first-page":"81","article-title":"Onchocerciasis elimination: progress and challenges","volume":"11","author":"Lakwo","year":"2020","journal-title":"Res. Rep. Trop. Med."},{"key":"10.1016\/j.pt.2024.07.005_bb0025","doi-asserted-by":"crossref","first-page":"e1186","DOI":"10.1016\/S2214-109X(20)30286-2","article-title":"The global distribution of lymphatic filariasis, 2000\u201318: a geospatial analysis","volume":"8","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.pt.2024.07.005_bb0030","series-title":"Manson\u2019s Tropical Disease","first-page":"745","article-title":"The Filariases","author":"Fischer","year":"2024"},{"key":"10.1016\/j.pt.2024.07.005_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2023.04.408","article-title":"First genome-wide association study for lymphatic filariasis in a West African population points to a human leukocyte antigen-mediated disease pathophysiology","volume":"133","author":"Grover","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40246-017-0121-7","article-title":"Single nucleotide polymorphisms in the angiogenic and lymphangiogenic pathways are associated with lymphedema caused by Wuchereria bancrofti","volume":"11","author":"Debrah","year":"2017","journal-title":"Hum. Genomics"},{"key":"10.1016\/j.pt.2024.07.005_bb0045","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/CMR.00057-10","article-title":"Onchocerciasis: the role of Wolbachia bacterial endosymbionts in parasite biology, disease pathogenesis, and treatment","volume":"24","author":"Tamarozzi","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.pt.2024.07.005_bb0050","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1093\/cid\/ciab191","article-title":"Modelling the impact of vector control on lymphatic filariasis programs: current approaches and limitations","volume":"72","author":"Davis","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.869039","article-title":"Advancing a Human onchocerciasis vaccine from antigen discovery to efficacy studies against natural infection of cattle with Onchocerca ochengi","volume":"12","author":"Zhan","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.pt.2024.07.005_bb0060","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1046\/j.1472-8206.2003.00170.x","article-title":"Ivermectin and filariasis","volume":"17","author":"Richard-Lenoble","year":"2003","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.pt.2024.07.005_bb0065","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s42003-020-01128-4","article-title":"Diethylcarbamazine activates TRP channels including TRP-2 in filaria, Brugia malayi","volume":"3","author":"Verma","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.pt.2024.07.005_bb0070","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1473-3099(23)00438-3","article-title":"The African eye worm: current understanding of the epidemiology, clinical disease, and treatment of loiasis","volume":"24","author":"Ramharter","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0075","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1517\/17460441.3.5.501","article-title":"Microtubules as antiparasitic drug targets","volume":"3","author":"Fennell","year":"2008","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.pt.2024.07.005_bb0080","article-title":"Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis","volume":"1","author":"Macfarlane","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pt.2024.07.005_bb0085","doi-asserted-by":"crossref","first-page":"729","DOI":"10.4269\/ajtmh.21-0731","article-title":"Impact of semi-annual albendazole on lymphatic filariasis and soil-transmitted helminth infection: parasitological assessment after 14 rounds of community treatment","volume":"106","author":"Pion","year":"2021","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2024.07.005_bb0090","doi-asserted-by":"crossref","first-page":"E176","DOI":"10.1093\/cid\/ciaa1232","article-title":"Results from 2 cohort studies in Central Africa show that clearance of Wuchereria bancrofti infection after repeated rounds of mass drug administration with albendazole alone is closely linked to individual adherence","volume":"73","author":"Campillo","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008322","article-title":"The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in the Democratic Republic of the Congo","volume":"14","author":"Pion","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0100","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1093\/cid\/ciz1050","article-title":"Efficacy and safety of a single dose of ivermectin, diethylcarbamazine, and albendazole for treatment of lymphatic filariasis in Cote d'Ivoire: an open-label randomized controlled trial","volume":"71","author":"Bjerum","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0105","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1473-3099(17)30175-5","article-title":"Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo","volume":"17","author":"Pion","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0110","series-title":"Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis","author":"WHO","year":"2017"},{"key":"10.1016\/j.pt.2024.07.005_bb0115","first-page":"489","article-title":"Global programme to eliminate lymphatic filariasis: progress report 2022","volume":"98","author":"WHO","year":"2023","journal-title":"Wkly Epidemiol. Rec."},{"key":"10.1016\/j.pt.2024.07.005_bb0120","first-page":"491","article-title":"Strategies and tools for the control\/elimination of lymphatic filariasis","volume":"75","author":"Ottesen","year":"1997","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.pt.2024.07.005_bb0125","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1473-3099(16)30467-4","article-title":"Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study","volume":"17","author":"Irvine","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0130","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A trial of a triple-drug treatment for lymphatic filariasis","volume":"379","author":"King","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2024.07.005_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2020.105677","article-title":"Onchocerciasis (river blindness)-more than a century of research and control","volume":"218","author":"Brattig","year":"2021","journal-title":"Acta Trop."},{"key":"10.1016\/j.pt.2024.07.005_bb0140","first-page":"572","article-title":"Elimination of human onchocerciasis: progress report, 2022-2023","volume":"98","author":"WHO","year":"2023","journal-title":"Wkly Epidemiol. Rec."},{"key":"10.1016\/j.pt.2024.07.005_bb0145","series-title":"Human and Animal Filariases","first-page":"283","article-title":"Drug Resistance in Filariae","author":"Prichard","year":"2022"},{"key":"10.1016\/j.pt.2024.07.005_bb0150","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1021\/acsinfecdis.9b00469","article-title":"Macrofilaricides: an unmet medical need for filarial diseases","volume":"6","author":"Hawryluk","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0155","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0140-6736(97)07081-5","article-title":"Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes","volume":"351","author":"Bockarie","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2024.07.005_bb0160","doi-asserted-by":"crossref","first-page":"804","DOI":"10.4269\/ajtmh.1993.49.804","article-title":"Comparison of single-dose diethylcarbamazine and ivermectin for treatment of bancroftian filariasis in Papua New Guinea","volume":"49","author":"Kazura","year":"1993","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2024.07.005_bb0165","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis","volume":"62","author":"Thomsen","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0170","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJMc1914262","article-title":"Single-dose triple-drug therapy for Wuchereria bancrofti \u2013 5-year follow-up","volume":"382","author":"King","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2024.07.005_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007325","article-title":"Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Cote d'Ivoire","volume":"13","author":"Edi","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009294","article-title":"An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia","volume":"15","author":"Supali","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002839","article-title":"The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: a multicenter, open-label, cluster-randomized study","volume":"16","author":"Weil","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2024.07.005_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009002","article-title":"A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis","volume":"15","author":"Krentel","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010096","article-title":"Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial","volume":"16","author":"Tavul","year":"2022","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0200","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S1473-3099(22)00026-3","article-title":"Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial","volume":"22","author":"Laman","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009069","article-title":"An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India","volume":"15","author":"Jambulingam","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0210","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/cid\/ciab202","article-title":"Individual efficacy and community impact of ivermectin, diethylcarbamazine, and albendazole mass drug administration for lymphatic filariasis control in Fiji: a cluster randomized trial","volume":"73","author":"Hardy","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008298","article-title":"Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study","volume":"14","author":"Dubray","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0220","first-page":"4","article-title":"Compressing the timelines for development and delivery: accelerating access to triple-drug therapy to eliminate lymphatic filariasis","volume":"106","author":"Jacobson","year":"2022","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2024.07.005_bb0225","first-page":"18","article-title":"Country reports on practical aspects of conducting large-scale community studies of the tolerability of mass drug administration with ivermectin\/diethylcarbamazine\/albendazole for lymphatic filariasis","volume":"106","author":"Jambulingam","year":"2022","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2024.07.005_bb0230","first-page":"26","article-title":"Accelerating the uptake of WHO recommendations for mass drug administration using ivermectin, diethylcarbamazine, and albendazole","volume":"106","author":"King","year":"2022","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2024.07.005_bb0235","first-page":"13","article-title":"Lessons from large-scale tolerability and acceptability studies of triple drug mass drug administration performed to support policy change and accelerate elimination of lymphatic filariasis","volume":"106","author":"Weil","year":"2022","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2024.07.005_bb0240","first-page":"39","article-title":"The importance of partnership in the rollout of triple-drug therapy to eliminate lymphatic filariasis in the Pacific","volume":"106","author":"Rainima-Qaniuci","year":"2022","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2024.07.005_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005163","article-title":"Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa","volume":"11","author":"Fischer","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0250","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s13071-023-05909-8","article-title":"The pipeline for drugs for control and elimination of neglected tropical diseases: 2. Oral anti-infective drugs and drug combinations for off-label use","volume":"16","author":"Pfarr","year":"2023","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.pt.2024.07.005_bb0255","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4269\/ajtmh.21-0859","article-title":"A reevaluation of the tolerability and effects of single-dose ivermectin treatment on Onchocerca volvulus microfilariae in the skin and eyes in Eastern Ghana","volume":"106","author":"Opoku","year":"2021","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2024.07.005_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011365","article-title":"A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis","volume":"17","author":"Opoku","year":"2023","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0265","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(17)32844-1","article-title":"Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial","volume":"392","author":"Opoku","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2024.07.005_bb0270","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14787210.2020.1792772","article-title":"Moxidectin: an oral treatment for human onchocerciasis","volume":"18","author":"Milton","year":"2020","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"10.1016\/j.pt.2024.07.005_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011633","article-title":"Safety and tolerability of moxidectin and ivermectin combination treatments for lymphatic filariasis in Cote d'Ivoire: a randomized controlled superiority study","volume":"17","author":"Bjerum","year":"2023","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0280","article-title":"Efficacy of moxidectin vs. ivermectin combination treatments for bancroftian filariasis in Cote d'Ivoire: preliminary 24 month results","author":"Koudou","year":"2023"},{"key":"10.1016\/j.pt.2024.07.005_bb0285","article-title":"Safety of mass drug coadministration with ivermectin, diethylcarbamazine, albendazole, and azithromycin for the integrated treatment of neglected tropical diseases: a cluster randomized community trial","volume":"18","author":"John","year":"2022","journal-title":"Lancet Reg. Health West Pac."},{"key":"10.1016\/j.pt.2024.07.005_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006184","article-title":"Mansonella perstans microfilaremic individuals are characterized by enhanced type 2 helper T and regulatory T and B cell subsets and dampened systemic innate and adaptive immune responses","volume":"12","author":"Ritter","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0295","first-page":"415","article-title":"Progress in eliminating onchocerciasis in the WHO Region of the Americas: doxycycline treatment as an end-game strategy","volume":"94","author":"WHO","year":"2019","journal-title":"Wkly Epidemiol. Rec."},{"key":"10.1016\/j.pt.2024.07.005_bb0300","article-title":"Current perspective of new anti-Wolbachial and direct-acting macrofilaricidal drugs as treatment strategies for human filariasis. GMS","volume":"10","author":"Ehrens","year":"2022","journal-title":"Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0305","first-page":"108","article-title":"Advances in antiwolbachial drug discovery for treatment of parasitic filarial worm infections","volume":"4","author":"Bakowski","year":"2019","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0310","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/1469-0691.12069","article-title":"The symbiotic role of Wolbachia in Onchocercidae and its impact on filariasis","volume":"19","author":"Bouchery","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.pt.2024.07.005_bb0315","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00430-007-0062-1","article-title":"Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study","volume":"197","author":"Hoerauf","year":"2008","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.pt.2024.07.005_bb0320","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00436-008-1217-8","article-title":"Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus","volume":"104","author":"Hoerauf","year":"2009","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.pt.2024.07.005_bb0325","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1756-3305-2-39","article-title":"Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in Cameroon","volume":"2","author":"Wanji","year":"2009","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.pt.2024.07.005_bb0330","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cis486","article-title":"Doxycycline improves filarial lymphedema independent of active filarial infection: a randomized controlled trial","volume":"55","author":"Mand","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0020092","article-title":"Doxycycline reduces plasma VEGF-C\/sVEGFR-3 and improves pathology in lymphatic filariasis","volume":"2","author":"Debrah","year":"2006","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2024.07.005_bb0340","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1017\/S0031182013001108","article-title":"Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis","volume":"141","author":"Taylor","year":"2014","journal-title":"Parasitology"},{"key":"10.1016\/j.pt.2024.07.005_bb0345","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijpddr.2014.09.001","article-title":"Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis","volume":"4","author":"Johnston","year":"2014","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.pt.2024.07.005_bb0350","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aao1551","article-title":"Identification and prioritization of novel anti-Wolbachia chemotypes from screening a 10,000-compound diversity library","volume":"3","author":"Johnston","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.pt.2024.07.005_bb0355","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41467-018-07826-2","article-title":"Industrial scale high-throughput screening delivers multiple fast acting macrofilaricides","volume":"10","author":"Clare","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2024.07.005_bb0360","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau2086","article-title":"Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis","volume":"11","author":"Taylor","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2024.07.005_bb0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007159","article-title":"Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity","volume":"13","author":"von Geldern","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0370","article-title":"Preclincial efficacy of the novel macrofilaricidal drug candidate ABBV-4083","author":"H\u00fcbner","year":"2019"},{"key":"10.1016\/j.pt.2024.07.005_bb0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011392","article-title":"A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity","volume":"17","author":"Alami","year":"2023","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1346068","article-title":"Combinations of the azaquinazoline anti-Wolbachia agent, AWZ1066S, with benzimidazole anthelmintics synergise to mediate sub-seven-day sterilising and curative efficacies in experimental models of filariasis","volume":"15","author":"Hegde","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.pt.2024.07.005_bb0385","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1073\/pnas.1816585116","article-title":"AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis","volume":"116","author":"Hong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.pt.2024.07.005_bb0390","doi-asserted-by":"crossref","DOI":"10.1002\/cpdd.1441","article-title":"A Phase 1, randomized, double-blind, placebo-controlled, single ascending dose trial of AWZ1066S, an Anti-Wolbachia candidate macrofilaricide","author":"Devereux","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.pt.2024.07.005_bb0395","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1039\/D2NP00012A","article-title":"Corallopyronin A: antimicrobial discovery to preclinical development","volume":"39","author":"Krome","year":"2022","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.pt.2024.07.005_bb0400","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1042\/BST20180499","article-title":"Mechanisms of antibiotics inhibiting bacterial RNA polymerase","volume":"47","author":"Mosaei","year":"2019","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.pt.2024.07.005_bb0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008930","article-title":"Corallopyronin A for short-course anti-wolbachial, macrofilaricidal treatment of filarial infections","volume":"14","author":"Schiefer","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fitd.2022.983107","article-title":"Pharmacology and early ADMET data of corallopyronin A, a natural product with macrofilaricidal anti-wolbachial activity in filarial nematodes","volume":"3","author":"Ehrens","year":"2022","journal-title":"Front. Trop. Diseases"},{"key":"10.1016\/j.pt.2024.07.005_bb0415","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00362-22","article-title":"Potent in vitro and ex vivo anti-gonococcal activity of the RpoB inhibitor Corallopyronin A","volume":"7","author":"Edwards","year":"2022","journal-title":"mSphere"},{"key":"10.1016\/j.pt.2024.07.005_bb0420","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3389\/fmicb.2019.00943","article-title":"Elaborations on Corallopyronin A as a novel treatment strategy against genital chlamydial infections","volume":"10","author":"Loeper","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.pt.2024.07.005_bb0425","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3390\/antibiotics11070920","article-title":"The RNA polymerase inhibitor corallopyronin A has a lower frequency of resistance than rifampicin in Staphylococcus aureus","volume":"11","author":"Balansky","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.pt.2024.07.005_bb0430","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/pharmaceutics15010131","article-title":"Pharmacokinetics and pharmacodynamics (PK\/PD) of Corallopyronin A against methicillin-resistant Staphylococcus aureus","volume":"15","author":"Rox","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pt.2024.07.005_bb0435","article-title":"Identification of new macrofilaricidal compounds for treatment of onchocerciasis","author":"H\u00fcbner","year":"2017","journal-title":"Proceeding of 66th Annual Meeting of the American Society for Tropical Medicine and Hygiene, Baltimore"},{"key":"10.1016\/j.pt.2024.07.005_bb0440","article-title":"Identification of potential clinical candidates with macrofilaricidal efficacy for the treatment of onchocerciasis","author":"Hawryluk","year":"2017","journal-title":"Proceeding of 66th Annual Meeting of the American Society for Tropical Medicine and Hygiene, Baltimore"},{"key":"10.1016\/j.pt.2024.07.005_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009682","article-title":"Development of emodepside as a possible adulticidal treatment for human onchocerciasis \u2013 the fruit of a successful industrial-academic collaboration","volume":"17","author":"Kr\u00fccken","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2024.07.005_bb0450","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13071-022-05581-4","article-title":"The pipeline for drugs for control and elimination of neglected tropical diseases: 1. Anti-infective drugs for regulatory registration","volume":"16","author":"Pfarr","year":"2023","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.pt.2024.07.005_bb0455","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003401","article-title":"Characterization of the Ca2+-gated and voltage-dependent K+-channel Slo-1 of nematodes and its interaction with emodepside","volume":"8","author":"Kulke","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0460","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijpddr.2021.07.005","article-title":"Evaluation of the in vitro susceptibility of various filarial nematodes to emodepside","volume":"17","author":"H\u00fcbner","year":"2021","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.pt.2024.07.005_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009601","article-title":"Emodepside targets SLO-1 channels of Onchocerca ochengi and induces broad anthelmintic effects in a bovine model of onchocerciasis","volume":"17","author":"Bah","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2024.07.005_bb0470","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijpddr.2022.10.002","article-title":"Diethylcarbamazine mediated potentiation of emodepside induced paralysis requires TRP-2 in adult Brugia malayi","volume":"20","author":"Kashyap","year":"2022","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.pt.2024.07.005_bb0475","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1111\/bcp.14816","article-title":"Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects","volume":"87","author":"Gillon","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pt.2024.07.005_bb0480","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa2212825","article-title":"Emodepside for Trichuris trichiura and hookworm infection","volume":"388","author":"Mrimi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2024.07.005_bb0485","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4269\/ajtmh.2012.11-0371","article-title":"Efficacy of diverse antiparasitic treatments for cysticercosis in the pig model","volume":"87","author":"Gonzalez","year":"2012","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2024.07.005_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008427","article-title":"Oxfendazole mediates macrofilaricidal efficacy against the filarial nematode Litomosoides sigmodontis in vivo and inhibits Onchocerca spec. motility in vitro","volume":"14","author":"H\u00fcbner","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0495","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/s41467-019-09442-0","article-title":"Mouse models of Loa loa","volume":"10","author":"Pionnier","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2024.07.005_bb0500","doi-asserted-by":"crossref","DOI":"10.3389\/fitd.2022.982421","article-title":"Comparison of the macrofilaricidal efficacy of oxfendazole and its isomers against the rodent filaria Litomosoides sigmodontis","author":"Risch","year":"2022","journal-title":"Front. Trop. Diseases"},{"key":"10.1016\/j.pt.2024.07.005_bb0505","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1091581815569582","article-title":"Preclinical studies on the pharmacokinetics, safety, and toxicology of oxfendazole: toward first in human studies","volume":"34","author":"Codd","year":"2015","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.pt.2024.07.005_bb0510","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/vr.111.8.161","article-title":"Toxicity study of oxfendazole in pregnant sows","volume":"111","author":"Morgan","year":"1982","journal-title":"Vet. Rec."},{"key":"10.1016\/j.pt.2024.07.005_bb0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007026","article-title":"Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk\/benefit to patients","volume":"13","author":"Lachau-Durand","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0520","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02255-18","article-title":"Pharmacokinetics, safety, and tolerability of oxfendazole in healthy volunteers: a randomized, placebo-controlled first-in-human single-dose escalation study","volume":"63","author":"An","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2024.07.005_bb0525","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01018-20","article-title":"Pharmacokinetics, safety, and tolerability of oxfendazole in healthy adults in an open-label phase 1 multiple ascending dose and food effect study","volume":"64","author":"Bach","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2024.07.005_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2019.103937","article-title":"Evolution of rifampicin treatment for tuberculosis","volume":"74","author":"Grobbelaar","year":"2019","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.pt.2024.07.005_bb0535","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00436-008-1133-y","article-title":"Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus","volume":"103","author":"Specht","year":"2008","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.pt.2024.07.005_bb0540","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41598-017-00322-5","article-title":"Short-course, high-dose rifampicin achieves Wolbachia depletion predictive of curative outcomes in preclinical models of lymphatic filariasis and onchocerciasis","volume":"7","author":"Aljayyoussi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pt.2024.07.005_bb0545","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","article-title":"A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis","volume":"191","author":"Boeree","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pt.2024.07.005_bb0550","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0555","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201712-2524OC","article-title":"Efficacy and safety of high-dose rifampin in pulmonary tuberculosis. a randomized controlled trial","volume":"198","author":"Velasquez","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pt.2024.07.005_bb0560","article-title":"Do costs, timeframes and attrition rates differ between non-commercial and commercial biomedical R&D?","author":"Moon","year":"2020"},{"key":"10.1016\/j.pt.2024.07.005_bb0565","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwad303","article-title":"AI enhances drug discovery and development","volume":"11","author":"Bai","year":"2024","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.pt.2024.07.005_bb0570","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s13071-022-05546-7","article-title":"Drugs for neglected tropical diseases: availability of age-appropriate oral formulations for young children","volume":"15","author":"Al-Obaidi","year":"2022","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.pt.2024.07.005_bb0575","article-title":"Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?","volume":"378","author":"Kura","year":"2023","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.pt.2024.07.005_bb0580","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/inthealth\/ihw027","article-title":"Antimalarial mass drug administration: ethical considerations","volume":"8","author":"Cheah","year":"2016","journal-title":"Int. Health"},{"key":"10.1016\/j.pt.2024.07.005_bb0585","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012211","article-title":"Sustaining the gains achieved by national neglected tropical disease (NTD) programs: how can we build NTD program country ownership and sustainability?","volume":"18","author":"Sodahlon","year":"2024","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0590","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-013686","article-title":"European priority review vouchers for neglected disease product development","volume":"9","author":"Ridley","year":"2024","journal-title":"BMJ Glob. Health"},{"key":"10.1016\/j.pt.2024.07.005_bb0595","first-page":"44","article-title":"Triple-drug treatment is effective for lymphatic filariasis microfilaria clearance in Samoa","volume":"6","author":"Graves","year":"2021","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.005_bb0600","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4269\/ajtmh.23-0255","article-title":"Surveillance and selective treatment of Brugia malayi filariasis eleven years after stopping mass drug administration in Belitung District, Indonesia","volume":"110","author":"Supali","year":"2024","journal-title":"Am. J. Trop. Med. Hyg."}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492224001818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492224001818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:57:40Z","timestamp":1778813860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471492224001818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":120,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1471492224001818"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2024.07.005","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The long and winding road towards new treatments against lymphatic filariasis and onchocerciasis","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2024.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}